glp 1 drugs and kidney function Renal effects of GLP-1 receptor agonists tirzepatide in individuals with type 2 diabetes: seeds of a promising future | Endocrine Frontiers | GLP-1 Receptor Agonists

An approach targeting both risk factors if they coexist is the basis for primary and secondary prevention of cardiovascular events

(OTCQB: ADIA), a leader in regenerative medicine through its subsidiary Adia Med, today announced an ambitious expansion of its clinical research pipeline, with plans to launch four to five additional studies throughout 2026

Among the tested matrices, M05 and M09 demonstrated better retention of viable cells during the later fermentation phase, as supported by both DeltaLog (CFUs) values trends

Note that in a study, the ADSC-EV-treated HDF proliferation shows an average of a 120% increase compared to the control [138]

CD38 degrades circulating NAD and its precursors NMN and NR, preventing NAD synthesis